Sanofi is paying €23m upfront to Belgium-based Ablynx NV for access to the latter company's Nanobody-based therapeutic platform; the pair will develop novel treatments for various immune mediated inflammatory diseases.
Under the agreement, Ablynx will receive research funding of around €8m for preclinical development of the initially selected targets. Sanofi...








